Literature DB >> 12680900

Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine.

Michael J Passmore1, Julie Garnham, Anne Duffy, Marsha MacDougall, Alana Munro, Claire Slaney, Andrew Teehan, Martin Alda.   

Abstract

OBJECTIVE: We conducted a study of clinical presentation and family history in patients responsive to either of two commonly used mood stabilizers, lithium and lamotrigine.
METHODS: The sample included 164 subjects from 21 families of bipolar probands, 14 responders to lithium and seven to lamotrigine. Diagnostic information on first-degree relatives was obtained in a blind fashion through a combination of direct interviews (SADS-L) and family history assessments (FH-RDC).
RESULTS: The probands differed with respect to clinical course (episodic in the lithium group, rapid cycling in the lamotrigine group), and comorbidity (panic attacks and substance abuse in the lamotrigine group). The relatives of lithium responders had significantly higher risk of bipolar disorder while relatives of lamotrigine responders had higher prevalence of schizoaffective disorder, major depression and panic attacks.
CONCLUSIONS: These findings suggest that lithium- and lamotrigine-responsive patients differ with respect to course of illness, comorbidity and family history and may represent distinct subtypes of bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12680900     DOI: 10.1034/j.1399-5618.2003.00026.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  25 in total

1.  The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment.

Authors:  Thomas G Schulze; Martin Alda; Mazda Adli; Nirmala Akula; Raffaella Ardau; Elise T Bui; Caterina Chillotti; Sven Cichon; Piotr Czerski; Maria Del Zompo; Sevilla D Detera-Wadleigh; Paul Grof; Oliver Gruber; Ryota Hashimoto; Joanna Hauser; Rebecca Hoban; Nakao Iwata; Layla Kassem; Tadafumi Kato; Sarah Kittel-Schneider; Sebastian Kliwicki; John R Kelsoe; Ichiro Kusumi; Gonzalo Laje; Susan G Leckband; Mirko Manchia; Glenda Macqueen; Takuya Masui; Norio Ozaki; Roy H Perlis; Andrea Pfennig; Paola Piccardi; Sara Richardson; Guy Rouleau; Andreas Reif; Janusz K Rybakowski; Johanna Sasse; Johannes Schumacher; Giovanni Severino; Jordan W Smoller; Alessio Squassina; Gustavo Turecki; L Trevor Young; Takeo Yoshikawa; Michael Bauer; Francis J McMahon
Journal:  Neuropsychobiology       Date:  2010-05-08       Impact factor: 2.328

2.  [S3 guidelines on bipolar disorders are contemporary and important instruments for clinical practice. Against].

Authors:  P Grof; B Müller-Oerlinghausen
Journal:  Nervenarzt       Date:  2013-07       Impact factor: 1.214

Review 3.  Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence.

Authors:  Anne Duffy
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

4.  Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial.

Authors:  James J Prisciandaro; Delisa G Brown; Kathleen T Brady; Bryan K Tolliver
Journal:  Psychiatry Res       Date:  2011-06-08       Impact factor: 3.222

5.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 6.  Response to treatment in bipolar disorder.

Authors:  Cristiana Cruceanu; Martin Alda; Guy Rouleau; Gustavo Turecki
Journal:  Curr Opin Psychiatry       Date:  2011-01       Impact factor: 4.741

7.  Predictors of lithium response in bipolar disorder.

Authors:  Sarah K Tighe; Pamela B Mahon; James B Potash
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

8.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 9.  Personalized Pharmacotherapy for Bipolar Disorder: How to Tailor Findings From Randomized Trials to Individual Patient-Level Outcomes.

Authors:  Joseph F Goldberg
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-07-16

10.  Lithium: a key to the genetics of bipolar disorder.

Authors:  Cristiana Cruceanu; Martin Alda; Gustavo Turecki
Journal:  Genome Med       Date:  2009-08-19       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.